Vanguard Intl Div Apprec Idx ETF
TRP’s Dividends: Key Drivers
TransCanada Corporation (TRP) is an energy infrastructure company in North America. Its revenue grew 11% in both 2016 and 9M17.
What Could Continue to Drive ENB’s Dividends
Enbridge (ENB) is involved in energy transportation in the United States and Canada. Revenue grew 2% in 2016, compared to 25% in 9M17.
What to Expect for Novartis’s Subsidiary Alcon in 2018
In 1Q17, 2Q17, and 3Q17, Novartis’s (NVS) subsidiary Alcon generated revenues of $1.4 billion, $1.5 billion, and $1.5 billion, respectively.
Novartis’s Crizanlizumab Demonstrates Positive Results in Trials
In December 2017, Novartis presented the results from the post-hoc subgroup analysis of the phase 2 Sustain trial.
What Analysts Recommend for Roche in January 2018
In December 2017, Roche and Ignyta entered a merger agreement where Roche will fully acquire Ignyta at a price of $27.0 per share in an all-cash transaction.
Perjeta Could Significantly Boost Roche’s Revenue Growth in 2018
In December 2017, the Food and Drug Administration approved Roche’s (RHHBY) Perjeta based on the results of its phase three Aphinity trial.
How Did Novo Nordisk’s Victoza and Saxendra Perform in 3Q17?
In 3Q17, Novo Nordisk’s (NVO) Victoza reported revenues of 5.3 billion Danish krone (or DKK), which reflected ~9% growth on a year-over-year (or YoY) basis.
Why Did MSFT’s Dividend Yield Fall in 2017?
Microsoft’s (MSFT) revenue rose 12% in 1Q18.
How Did DVN’s Dividend Cut Affect Its Dividend Yield?
Devon Energy Corporation’s 56.0% dividend cut in 2016 was followed by a 43.0% cut in 2017.
Inside Novartis’s Ophthalmology Drugs Now
In 3Q17, Novartis’s (NVS) Lucentis generated revenues of ~$481 million, which was ~5% higher YoY (year-over-year) and 1% higher QoQ (quarter-over-quarter).
Roche’s Tarceva, Actemra, and Esbriet in 3Q17
In 3Q17, Roche Holding’s (RHHBY) Actemra generated revenues of 485 million Swiss francs, which reflected ~13% growth on a year-over-year (or YoY) basis.
What Affected CAE’s Dividend Yield?
CAE (CAE) is an international frontrunner in the delivery of training for the civil aviation, defense and security, and healthcare markets.
How Roche’s Rituxan and Acterma Are Positioned after 1H17
In the first half of 2017, Roche’s (RHHBY) Rituxan/MabThera reported revenues of CHF 3.8 billion, which is a 3.0% rise on a YoY basis.
Esbriet Could Boost Roche’s Revenue Growth in 2H17
In the first half of 2017, Roche’s (RHHBY) Esbriet reported revenues of CHF 418.0 million, which reflected a ~16.0% growth on a YoY basis.
How Is Novo Nordisk’s Victoza Positioned after 2Q17?
In the first half of 2017, Novo Nordisk’s (NVO) Victoza generated revenues of DKK (Danish kroner) 11.5 billion, which reflected a ~21.0% rise on a YoY (year-over-year) basis.
Welltower’s Dividend Yield Falls despite Higher Dividend
Revenue and earnings In this part, we’ll look at Welltower (HCN), a US healthcare REIT. Welltower’s revenue growth slowed from 15% in 2015 to 11% in 2016. The growth was driven by all of its segments, through rental income, resident fees and services, interest income, and other income. Its operating costs and other expenses (including interest expenses) […]
Behind TEVA’s Women’s Health Products after 1H17
In 1H17, Teva Pharmaceutical’s (TEVA) women’s health business reported revenues of ~$239 million, or ~5% higher YoY (year-over-year).
Fresenius Medical Care Is a Global Leader in the Dialysis Segment
In addition to selling dialysis products, Fresenius Medical Care also offers dialysis treatment and associated laboratory services to patients through its network of 3,690 clinics.
Could SEG101 Revolutionize the Treatment for Sickle Cell Disease?
Novartis (NVS) is currently involved in developing its investigational therapy SEG101 for sickle cell disease.
Novartis Aims to Turn Around Its Surgical Business in 2017
In 2016, the surgical business of Alcon, Novartis’s (NVS) Consumables segment, witnessed a solid demand trend.
What Could Boost Medicare Demand for Novartis’s Entresto?
If Novartis manages to further improve access to Entresto in 2017, it could have a favorable impact on the company’s stock and the Vanguard International Dividend Appreciation ETF (VIGI).